RxDoctor Payments Data

John Velky, MD

Family Medicine · North Augusta, SCNPI 1659307593

Payments from drug & device makers

$14,042in general payments, 2019–2025

Across 841 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$993
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$13,96199%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)127$1,794
AstraZeneca96$1,547
Lilly USA, LLC67$1,221
Novo Nordisk72$1,185
Pfizer70$1,092
Takeda Pharmaceuticals U.S.A., Inc.64$993
GSK33$485
Novartis22$422
Boehringer Ingelheim19$361
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$347
Otsuka America Pharmaceutical, Inc.14$322
Amgen17$309
Astellas Pharma US Inc10$238
Biohaven Pharmaceutical Holding Company Ltd.10$230
Merck16$218
Corium, LLC13$197
Exact Sciences10$187
Ironshore Pharmaceuticals Inc.8$175
Phathom Pharmaceuticals, Inc.11$171
Sanofi-aventis U.S. LLC10$167
Ironwood Pharmaceuticals, Inc8$153
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)8$151
Antares Pharma, Inc.7$125
Dexcom, Inc.7$123
Idorsia Pharmaceuticals US Inc6$120
Collegium Pharmaceutical, Inc.6$111
Eisai Inc.6$94
Neos Therapeutics, LP6$94
Biohaven Pharmaceuticals, Inc.4$90
Halozyme Inc5$82
Bayer4$82
Amarin Pharma, Inc.5$80
Axsome Therapeutics, Inc.4$76
Nevro Corp.2$70
Adlon Therapeutics L.p.4$70
Paratek Pharmaceuticals, Inc.3$59
Supernus Pharmaceuticals, Inc.3$58
Esperion Therapeutics, Inc.3$55
Kowa Pharmaceuticals America, Inc.4$54
Tris Pharma Inc3$53
Tolmar, Inc.3$53
Clarus Therapeutics Inc.3$40
Corcept Therapeutics2$39
Jazz Pharmaceuticals Inc.2$39
Johnson & Johnson2$36
Aytu Biopharma, Inc.1$31
Edwards Lifesciences1$30
Amneal Pharmaceuticals LLC2$29
Endo Pharmaceuticals Inc.2$29
Abiomed1$28
Inspire Medical Systems, Inc.1$27
Bausch Health US, LLC1$25
Verity Pharmaceuticals Inc.1$24
Acadia Pharmaceuticals Inc1$22
Daiichi Sankyo Inc.1$19
Genentech USA, Inc.1$17
Currax Pharmaceuticals LLC1$15
Boston Scientific1$15
E.r. Squibb & Sons, L.L.C.1$13
Gilead1$13

How this compares

$14,042 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$314,992
Medicare patients
961
Services billed
13,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide182$222,956
MounjaroTirzepatide146$198,767
EliquisApixaban202$164,131
FarxigaDapagliflozin Propanediol145$132,020
TrulicityDulaglutide112$114,122
JardianceEmpagliflozin84$88,372
JanuviaSitagliptin Phosphate42$47,776
XareltoRivaroxaban34$40,040
EntrestoSacubitril/Valsartan35$34,078
CreonLipase/Protease/Amylase40$34,007
Tresiba Flextouch U-200Insulin Degludec37$27,767
Lantus SolostarInsulin Glargine,hum.Rec.Anlog90$25,422
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$23,864
JanumetSitagliptin Phos/Metformin Hcl36$23,474
ProliaDenosumab13$22,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,221$312,889258 claims
Novo NordiskOzempic, Rybelsus$1,185$240,458201 claims
PfizerEliquis$1,092$164,131202 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,547$159,406202 claims
Boehringer IngelheimJardiance$361$88,37284 claims
MerckJanuvia, Janumet$218$71,25078 claims
AbbVieCreon, Linzess, Synthroid$1,794$56,503192 claims
Johnson & JohnsonXarelto$36$40,04034 claims
NovartisEntresto$422$34,07835 claims
GSKTrelegy Ellipta, Breo Ellipta$485$31,40550 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix, Dexilant$993$23,45556 claims
AmgenProlia$309$22,36413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in North Augusta

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →